Mannkind Corp
MNKD
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.05B
Close$
$4.94
54.8% upside
Current Fair Value
54.8% upsideUndervalued by 54.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.05 Billion |
|---|---|
| Enterprise Value | $1.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.02 |
| Beta | 1.08 |
| Outstanding Shares | 309,191,000 |
Return
| Return on Equity | 64.90% |
|---|---|
| Return on Assets | -5.96% |
| Return on Invested Capital | 2.71% |
Valuation & Multiples
| P/E Ratio | -23.58 |
|---|---|
| PEG | 0.8 |
| Price to Sales | 3.19 |
| Price to Book Ratio | -3.19 |
| Enterprise Value to Revenue | 3.4 |
| Enterprise Value to EBIT | 83.78 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | -5.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$108.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$109.49 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 138.19% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 59.81% |
|---|---|
| Total Invested | $48,134▼ 99.99% |
| Investors Holding | 4▼ 264.00% |
ESG Score
No data
About Mannkind Corp
233 employees
CEO: Michael Castagna MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...